FDA-approved
Bones & muscles
Etelcalcetide
Evidence
FDA approved
Class
Calcimimetic peptide
KEY TAKEAWAY
Etelcalcetide is a synthetic peptide that mimics calcium at the calcium-sensing receptor. It is sold as Parsabiv. The FDA approved etelcalcetide (Parsabiv) in 2017 for secondary hyperparathyroidism in adults with chronic kidney disease on hemodialysis.
Written by the Veylo editorial team · Updated
November 2026
What it is
Calcimimetic peptide
Approved for
Secondary hyperparathyroidism in adults on hemodialysis
Key fact
The FDA approved etelcalcetide (Parsabiv) in 2017 for secondary hyperparathyroidism in adults with chronic kidney disease on hemodialysis.
Route
Intravenous injection at the end of dialysis
Evidence strength
FDA approved
Etelcalcetide is a synthetic peptide that mimics calcium at the calcium-sensing receptor. It is sold as Parsabiv.
It activates the calcium-sensing receptor on the parathyroid gland, which lowers the release of parathyroid hormone.
The FDA approved etelcalcetide (Parsabiv) in 2017 for secondary hyperparathyroidism in adults with chronic kidney disease on hemodialysis.
Secondary hyperparathyroidism in adults on hemodialysis.
Low blood calcium, nausea, vomiting and muscle spasms are the main effects.
U.S. FDA prescribing information for Etelcalcetide. DailyMed, National Library of Medicine.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.